EUCTR2016-001253-41-IT进行中（未招募）1 期
Impact of cabazitaxel on metastatic bone disease in patients with castration resistant prostate cancer previously treated with docetaxel - CABONE STUDY
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 107
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Histologically or cytologically confirmed adenocarcinoma of prostate that is resistant to hormone therapy and previously treated with a docetaxel containing regimen
- •2.At least one measurable bone metastasis showed with bone scan and radiological confirmed. A confirmed diagnosis of bone metastases to bone scanning will require a second imaging modality (CT, MRI, or plain radiograph)
- •3.Life expectancy > 3 months
- •4.Eastern Cooperative Oncology Group (ECOG) performance status 0 – 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 107
排除标准
- •1. History of visceral metastasis, or visceral metastases as assessed by abdominal/pelvic CT or chest x-ray within previous 8 weeks
- •2.Any previous hormonal therapy with abiraterone, enzalutamide, TAK 700 provided in post docetaxel setting. Abiraterone pre-docetaxel is allowed only if the last administration is more than 3 months before the study inclusion
研究者
相似试验
已完成
2 期
Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells KineticProstate CarcinomaCastration-resistant Prostate CancerCirculating Tumor CellsChemotherapyNCT03101046UNICANCER40
进行中（未招募）
1 期
Phase II trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcomaocally advanced dedifferentiated liposarcomaMedDRA version: 19.0Level: PTClassification code 10073135Term: Dedifferentiated liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003672-39-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)50
进行中（未招募）
1 期
Phase II trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma.ocally advanced dedifferentiated liposarcomaMedDRA version: 19.1Level: PTClassification code 10073135Term: Dedifferentiated liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003672-39-NLEuropean Organisation for Research and Treatment of Cancer (EORTC)50
进行中（未招募）
1 期
Phase II trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcomaEUCTR2012-003672-39-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)50
已完成
2 期
Study of the Effect of Chemotherapy With Cabazitaxel on Prostate CancerBone Metastatic Prostate CancerNCT02512458Hellenic Cooperative Oncology Group60